Akineton and Beconase AQ eent

• Generic Name: biperiden
• Dosage Forms: Tablets
• Other Brand Names: Akineton

Biperiden is used alone or together with other medicines (e.g., levodopa) to treat Parkinson's disease. By improving muscle control and reducing stiffness, this medicine allows more normal movements of the body as the disease symptoms are reduced.

Biperiden is also used to control severe muscle reactions and other side effects from certain medicines that are used to treat severe nausea or nervous, mental, or emotional conditions (e.g., chlorpromazine [Thorazine®], perphenazine [Trilafon®], prochlorperazine [Compazine®], promethazine [Phenergan®], thioridazine [Mellaril®]).

This medicine is available only with your doctor's prescription.

• Generic Name: beclomethasone nasal
• Dosage Forms: nasal spray, suspension
• Other Brand Names: Beconase AQ, QNASL, Beconase, Vancenase, Vancenase AQ, Vancenase AQ DS, QNASL

Symptomatic treatment of seasonal or perennial rhinitis.

Generally provides symptomatic relief of watery rhinorrhea, nasal congestion, sneezing (including morning sneezing attacks), and nasal and pharyngeal itching.

Generally does not relieve signs and symptoms of conjunctivitis or those involving the lower respiratory tract (e.g., coughing), although improvement in ophthalmic and respiratory manifestations may occur.

Relieves symptoms in both allergic and nonallergic rhinitis, although intranasal route appears to provide greater relief in allergic rhinitis.

Continuous concomitant therapies (e.g., oral or orally inhaled corticosteroids, bronchodilators, antihistamines, decongestants) may be required for optimum symptomatic relief, especially in patients with concurrent asthmatic conditions.

Symptomatic relief is usually evident within several days of initiating continuous intranasal therapy; however, up to 2 weeks may be required for optimum effectiveness.

Used principally to prevent nasal polyp recurrence after surgical removal.

May delay need for subsequent surgery, but should not preclude polypectomy when polyp size prevents adequate penetration of drug into nasal passages.

May reduce polyp size and the degree of nasal obstruction, but apparently does not alter underlying disease; manifestations usually recur when the drug is discontinued.

Periodically monitor patients receiving prolonged intranasal corticosteroid therapy with rhinoscopic examinations, since risk for atrophic rhinitis is increased.